Viking starts SUNRISE Phase 3 program for oral VK2735 in obesity
Two 68-week trials will each enroll 560 adults across multiple dose arms, running alongside the fully enrolled VANQUISH injectable studies.
PR
By Priya Raman · Science Reporter
Oct 17 16:36 ETSource: Simply Wall Street
The wire
- 01Viking Therapeutics has launched the SUNRISE Phase 3 program testing oral VK2735, a dual GLP-1/GIP agonist, in two 68-week trials of 560 adults each, covering non-diabetic and type 2 diabetic obesity.
- 02The oral program extends a pipeline that already includes the fully enrolled VANQUISH injectable trials and an expanded maintenance dosing study, adding another oral incretin option to watch.
- 03Viking reports no revenue and a $359.6 million annual loss, so any efficacy or tolerability signal in SUNRISE or VANQUISH would echo across the entire program; this write-up is investor commentary, not company data.
From the source
Read at simplywall.stViking Therapeutics Stock In Focus As Earnings Near And Obesity Trial Advances
Scan beyond Viking Therapeutics and line up other obesity and metabolic names that could be setting up for the next move with the hand picked 33 healthcare AI stocks .
